Sabine Wittemer-Rump Selected Research

aprutumab ixadotin

10/2019	First-in-Human Phase I Study of Aprutumab Ixadotin, a Fibroblast Growth Factor Receptor 2 Antibody-Drug Conjugate (BAY 1187982) in Patients with Advanced Cancer.
11/2016	Preclinical Efficacy of the Auristatin-Based Antibody-Drug Conjugate BAY 1187982 for the Treatment of FGFR2-Positive Solid Tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Sabine Wittemer-Rump Research Topics

Disease

4	Neoplasms (Cancer) 01/2021 - 11/2016
2	Stomach Neoplasms (Stomach Cancer) 10/2019 - 05/2018
1	Prostatic Neoplasms (Prostate Cancer) 01/2021
1	Bites and Stings (Sting) 01/2021
1	Proteinuria 10/2019
1	Body Weight (Weight, Body) 10/2019
1	Triple Negative Breast Neoplasms 10/2019
1	Thrombocytopenia (Thrombopenia) 10/2019
1	Anemia 10/2019

Drug/Important Bio-Agent (IBA)

3	Fibroblast Growth Factor Receptors (Fibroblast Growth Factor Receptor)IBA 10/2019 - 11/2016
2	Immunoconjugates (Immunoconjugate)IBA 10/2019 - 11/2016
2	aprutumab ixadotinIBA 10/2019 - 11/2016
1	PasotuxizumabIBA 01/2021
1	Pharmaceutical PreparationsIBA 10/2019
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 10/2019
1	Aspartate Aminotransferases (Aspartate Transaminase)IBA 10/2019
1	Messenger RNA (mRNA)IBA 05/2018
1	auristatinIBA 11/2016

Therapy/Procedure

1	Castration 01/2021
1	Therapeutics 01/2021